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3 according to the International Staging System ( p =  0.006) 
as adverse risk factors regarding PFS. Median OS was sig-
nificantly better in newly diagnosed MM patients receiving 
induction therapy with novel agents, e.g., bortezomib, tha-
lidomide, or lenalidomide, compared with a traditional reg-
imen (69 vs. 58 months;  p =  0.01). More patients achieved at 
least a very good partial remission in the period from 2005 
to 2012 than from 1996 to 2004 (65 vs. 30%;  p < 0.001), with 
a longer median OS in the later period (71 vs. 52 months, 
 p = 0.027). In conclusion, our analysis confirms HDCT-ASCT 
as an effective therapeutic strategy in an unselected large 
myeloma patient cohort with a low TRD rate and improved 
prognosis due to novel induction strategies. 
 © 2017 S. Karger AG, Basel 
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 Abstract 
 Within this retrospective single-center study, we analyzed 
the survival of 320 multiple myeloma (MM) patients receiv-
ing melphalan high-dose chemotherapy (HDCT) and either 
single ( n = 286) or tandem ( n = 34) autologous stem cell 
transplantation (ASCT) from 1996 to 2012. Additionally, the 
impact of novel induction regimens was assessed. Median 
follow-up was 67 months, median overall survival (OS) 62 
months, median progression-free survival (PFS) 33 months 
(95% CI 27–39), and treatment-related death (TRD) 3%. Mul-
tivariate analysis revealed age  ≥ 60 years ( p =  0.03) and stage 
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 Introduction 
 Particularly for younger and fit patients with newly 
 diagnosed multiple myeloma (NDMM), the melphalan 
high-dose chemotherapy (HDCT) with autologous stem 
cell transplantation (ASCT) regimen is superior to con-
ventional chemotherapy regarding response rate, event-
free survival (EFS), and in part also overall survival (OS). 
Thus, HDCT-ASCT established as standard multiple my-
eloma (MM) therapy  [1–4] . Together with other B-cell 
lymphomas, it remains the most frequent indication for 
ASCT worldwide  [5, 6] . 
 Nevertheless, median duration of response after 
HDCT-ASCT is documented as less than 3 years, and the 
majority of patients experience relapse  [7] . Particularly 
for older patients and patients with refractory myeloma, 
ASCT failed to show significant advantage concerning 
survival  [8, 9] . Furthermore, tandem ASCT with 2 succes-
sive high-dose melphalan regimens within 6 months 
(preferably within 3) was introduced  [10–13] .
 Starting in the late 1990s, treatment of patients with 
MM improved with regard to survival upon the introduc-
tion of new drugs, including the proteasome inhibitor 
bortezomib, the immunomodulatory drug thalidomide, 
and their respective second-generation compounds, e.g., 
lenalidomide. These novel therapies were first applied to 
NDMM, refractory, and/or relapsed MM (RRMM) pa-
tients  [14–22] . Later, they were also used as part of prepa-
ratory regimens before ASCT and as part of consolidation 
and/or maintenance therapy  [23–27] . Besides, the use of 
these novel drugs as part of maintenance therapy follow-
ing melphalan HDCT-ASCT was shown to improve EFS 
and OS in case of thalidomide and progression-free sur-
vival (PFS) as well as EFS in case of lenalidomide, respec-
tively  [28–30] . Recently, the 3-drug combination of le-
nalidomide, bortezomib, and dexamethasone (RVD) as 
induction and consolidation with ASCT followed by 
maintenance therapy with lenalidomide resulted in con-
vincing estimated 3-year PFS of 77% and 3-year OS of 
100%  [31] . 
 In order to review the efficacy and toxicity for all my-
eloma patients treated in the Department of Hematology 
and Oncology at the University of Münster Hospital with 
single or  tandem ASCT without selection criteria for spe-
cific studies, we conducted a retrospective analysis in the 
period from 1996 to 2012. Additionally, we studied the 
impact of induction therapy containing novel compounds 
on the outcome of myeloma patients receiving ASCT in 
our Department.
 Patients and Methods 
 Data of myeloma patients receiving single or tandem ASCT fol-
lowing melphalan HDCT were available for the period from Octo-
ber 1996 to August 2012, which allowed us to analyze 320 con-
secutive patients altogether retrospectively. Eligibility criteria for 
ASCT for these patients were age  ≤ 75 years, a suitable Eastern 
Cooperative Oncology Group  performance status, and the lack of 
significant comorbidities or multiple organ dysfunctions. Patients 
with cytogenetic high-risk constellation or an insufficient hemato-
logical response after the first ASCT (partial remission, PR, or 
worse) were offered the tandem ASCT modality. Single ASCT was 
applied to 286 and tandem ASCT to 34 patients.  The characteris-
 Table 1.  Patient characteristics at diagnosis: entire cohort
Entire cohort (n = 320) n %
Male 191 60
Female 129 40
Multiple myeloma type
Unavailable 2 <1
Available 318 99
IgG κ 127 40
IgG λ 54 17
IgA κ 29 9
IgA λ 53 17
IgD κ 1 <1
κ 31 10
λ 17 5
Nonsecretory 4 1
Biclonal 2 <1
Durie-Salmon stage
Unavailable 48 15
Available 272 85
IA 23 8
IB 5 2
IIA 26 10
IIB 7 3
IIIA 162 59
IIIB 49 18
ISS stage
Unavailable 108 34
Available 212 66
1 90 42
2 80 38
3 42 20
Cytogenetic risk stratification at diagnosis
Unavailable 193 60
Available 127 40
Standard risk 101 80
Intermediate risk 7 5
High risk 19 15
 The median age of the patients was 56 years (range: 35 – 74). ISS, 
International Staging System; available, detailed information 
available. 
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tics of the patients are given in  Table 1 as well as in online supple-
mentary Tables 1 and 2 (for all online suppl. material, see www.
karger.com/doi/10.1159/000463534). All patients provided writ-
ten informed consent before therapy. This retrospective evaluation 
has been approved by the Ethics Board of the Faculty of Medicine 
at the Westfälische Wilhelms University of Münster and the Physi-
cians Chamber of Westfalen-Lippe (permit No. 2014-039-f-N).
 Treatment response was evaluated according to the Interna-
tional Myeloma Working Group  criteria  [32] . The objectives of 
our study were to investigate OS, PFS, hematological response, and 
treatment-related death (TRD).
 Four patients  were participating in an autologous/allogeneic 
sequential transplantation treatment study  [33] . After ASCT and 
upon relapse/progression, patients were offered to participate in 
 several rescue studies, e.g., with the triple angiokinase inhibitor 
BIBF 1120  [34] , the receptor tyrosine kinase inhibitor SU6668 
 [35] , or other novel drugs [unpubl. data]  [16, 19, 20] . Cytogenetic 
risk stratification by conventional cytogenetics and/or FISH anal-
ysis from bone marrow at diagnosis was available in 127 patients 
(40%). Patients who had 1 or more of the following abnormali-
ties – t(4; 14), t(14; 16), t(14; 20), del(17p), and/or gain of 1q21 – 
were categorized as high risk  [36] . Patients with t(11; 14) were con-
sidered of intermediate risk. All other karyotypes, including 13q 
deletion and cases without cytogenetic abnormalities by chromo-
some banding/FISH were considered standard risk.
 Table 2.  Myeloma therapies and hematological response
Entire cohort
(n = 320)
n %
Induction therapies
Number/patient Unavailable 41 13
Available 279 87
1 176 63
2 83 30
3 18 6
5 2 <1
Type/patient Unavailable 40 12
Available 280 88
Traditional 156 56
Novel 124 44
Novel therapy types1 Thalidomide based 9 3
Bortezomib based 113 40
 Lenalidomide based 12 4
 VTD 2 <1
Therapies after ASCT 
Consolidation Unavailable 156 49
Available 164 51
Yes 15 9
No 149 91
Consolidation Bortezomib 12 7
Maintenance/patient Unavailable 129 40
Available 191 60
Yes 55 29
No 136 71
Maintenance, total Interferon 44 23
Lenalidomide based 5 3
Dexamethasone based 1 <1
Bortezomib based 2 1
Thalidomide based 6 3
Salvage chemotherapy Unavailable 165 52
Available 155 48
Yes 138 89
No 17 11
Type of salvage 
therapy/patient
Traditional 36 26
Novel 102 74
Salvage transplant Unavailable 183 57
Available 137 43
Yes 26 19
No 111 81
ASCT 16 62
Allogeneic 9 35
Autologous-allogeneic 1 4
Entire cohort
(n = 320)
n %
Hematological response
Before ASCT Unavailable 50 16
Available 270 84
sCR 1 <1
CR 22 8
VGPR 43 16
PR 153 57
SD 33 12
PD 18 7
After ASCT 
(day +100)
Unavailable 63 20
Available 257 80
sCR 1 <1
CR 49 19
VGPR 80 31
PR 103 40
SD 12 5
PD 12 5
At the last follow-up Unavailable 88 27
Available 232 73
sCR 4 2
CR 35 15
 VGPR 30 13
 PR 46 20
 SD 19 8
 PD 98 42
 Available, detailed information available; CR, complete remis-
sion; sCR, stringent CR; PR, partial remission; VGPR, very good 
PR; SD, stable disease; PD, progressive disease; VTD, Velcade/tha-
lidomide/dexamethasone; ASCT, autologous stem cell transplan-
tation. 
1 Types of novel induction therapies (n = 136) in total (patient 
independent). 
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 Detailed information about the procedures of stem cell mobi-
lization and peripheral blood stem cell collection as well as mel-
phalan HDCT and ASCT can be found as online supplementary 
information 1.
 Statistical Methods 
 Statistical analysis was performed with the support of the Sta-
tistical Package for Social Sciences (SPSS 22, released 2013, IBM 
SPSS Statistics for Windows, version 22.0; IBM Corp., Armonk, 
NY, USA). OS was calculated starting from the day of the first 
ASCT (day 0) until death from any reason with censoring of pa-
tients alive at their last follow-up. PFS in terms of death or progres-
sion was measured from the day of ASCT to the day of document-
ed death, progression, or relapse, respectively. PFS for patients be-
ing alive and in remission was censored at the last follow-up. TRD 
was determined as death from any cause other than progression or 
relapse before day +100 from the last ASCT in patients with a fol-
low-up of at least 100 days after the last ASCT. Thus, patients with 
a follow-up <100 days after ASCT were excluded from TRD anal-
ysis. The Fisher exact test was used for categorical variables, and 
the Mann-Whitney U test was used for continuous variables. OS 
and PFS were estimated with the Kaplan-Meier method; log-rank 
tests with a 95% confidence interval (95% CI) were used for com-
parison of time-dependent outcome measures.  p values <0.05 were 
considered as indicating statistically significant differences. Me-
dian follow-up was calculated by reverse censoring.
 Potent covariates with impact on OS and PFS were calculated 
by Cox regression analysis with respective hazard ratios (HR) and 
Wald test  p values adjusted for age and gender. For Cox regression 
analysis of PFS with backward likelihood ratio variable selection, 
82 patients of the entire cohort with available data on the chosen 
covariates age at diagnosis ( ≤ 60 vs. >60 years), gender, cytogenet-
ic risk, International Staging System (ISS) stage, and induction 
therapy have been included. For Cox regression analysis of OS 
without variable selection, 95 patients of the entire cohort with 
complete data have been included. 
 Results  
 The baseline characteristics of the entire cohort as well 
as detailed information about the single and tandem 
ASCT groups are listed in  Table 1 as well as in online sup-
plementary Tables 1 and 2. Overall, a total of 320 patients 
with symptomatic MM (191 males and 129 females; male 
female ratio 1.5) were evaluated for this retrospective 
analysis. The median age at diagnosis was 57 years (range 
35–74), and the median age at ASCT was 58 years (range 
35–75). TRD was 3%. The majority of the patients ( n = 
162; 59%) was diagnosed with Durie-Salmon stage IIIA 
( Table 1 ). ISS 1 was most frequent ( n = 90 patients; 42%) 
followed by ISS 2 ( n = 80 patients; 38%). Before ASCT, 
19% of the patients ( n = 51) were in stable or progressive 
disease ( Table 2 ).
 Patient Outcome with regard to Prognostic Factors 
 At a median follow-up of 67 months (95% confidence 
interval, 60.0–74.0), the median OS and PFS for the entire 
cohort were 62 months (95% CI 51.3–72.7) and 33 months 
(95% CI 27.0–39.0), respectively. Five years after ASCT, 
OS was 51% (SE 3.6) and PFS was 27% (SE 3.4). There was 
no significant difference between males and females with 
regard to OS and PFS ( Table 3 ,  and data not shown). Pa-
tients >60 years at the time of ASCT had a significantly 
worsened PFS as compared to those aged  ≤ 60 years (me-
dian 26 vs. 41 months,  p < 0.001;  Fig.  1 a), whereas there 
was only a nonsignificant trend for OS (median 49 vs. 68 
months;  p =  0.074; data not shown). There was no sig-
nificant difference in survival between patients aged  ≤ 65 
and >65 years at the time of ASCT (data not shown). Age 
 ≤ 60 versus >60 years at diagnosis was an independent 
 Table 3.  Multi- and univariate Cox proportional-hazards regres-
sion of prognostic factors for progression-free (PFS) and overall 
survival (OS)
Covariate p
value1
HR 95% CI
Multivariate Cox proportional-hazards regression with 
backward likelihood ratio variable
PFS Age (≤60 vs. >60 years)2 0.030 1.922 1.1 – 3.5
ISS stage 0.023
ISS 1 vs. ISS 2 0.107
ISS 1 vs. ISS 3 0.006 2.599 1.3 – 5.1
OS SG-1 vs. SG-2 after ASCT 0.021 2.860 1.2 – 7.0
Univariate Cox proportional-hazards regression
PFS Age (≤60 vs. >60 years)2 0.011 1.562 1.1 – 2.2
Gender (male vs. female) 0.518
Cytogenetic risk 0.037
(SR vs. IR) 0.269
(SR vs. high risk) 0.015 2.398 1.2 – 4.9
β2-MG (≤3.5 vs. >3.5 mg/L) 0.004 1.698 1.2 – 2.4
ISS stage 0.001
ISS 1 vs. ISS 2 0.032 1.573 1.0 – 2.4
ISS 1 vs. ISS 3 <0.001 2.425 1.5 – 3.9
SG-1 vs. SG-2 before ASCT 0.156
SG-1 vs. SG-2 after ASCT 0.630
OS SG-1 vs. SG-2 before ASCT 0.007 2.303 1.3 – 4.2
SG-1 vs. SG-2 after ASCT 0.001 1.967 1.3 – 2.9
 Adequate information was available for 238 patients. Reference 
categories are in italics. HR, hazard ratio; 95% CI, 95% confidence 
interval; ISS, International Staging System; SG, subgroup; SR, stan-
dard risk; IR, intermediate risk. 38 patients from the single ASCT 
cohort were censored at the last contact due to missing data for 
survival analysis. 
1 Wald test p values adjusted for age and gender.
2 Age at diagnosis.
D
ow
nl
oa
de
d 
by
: 
Sp
ita
l N
et
z 
Be
rn
 A
G
   
   
   
   
   
   
   
   
   
   
   
   
16
1.
62
.2
52
.4
0 
- 5
/1
1/
20
17
 4
:1
1:
56
 P
M
 High-Dose Melphalan in Multiple 
Myeloma 
 Acta Haematol 2017;137:163–172 
DOI: 10.1159/000463534
167
prognostic factor for PFS in univariate ( p =  0.011, HR 
1.562, 95% CI 1.1–2.2) as well as in multivariate analysis 
( p =  0.030, HR 1.922, 95% CI 1.1–3.5;  Table 3 ). ISS 3 at 
the time of diagnosis was significantly associated with 
worse PFS compared to ISS 1 and ISS 2 (PFS for ISS 1 = 
48 months, ISS 2 = 27 months, and ISS 3 = 17 months;  p 
=  0.002; further data not shown) and proved to be an in-
dependent prognosticator for PFS in multivariate analy-
sis (ISS 1 vs. ISS 3;  p =  0.006, HR 2.599, 95% CI 1.3–5.1; 
 Table  3 ). Patients with an initial β 2 -microglobulin (β 2 -
MG) level >3.5 mg/L had a significantly shorter PFS than 
patients with a β 2 -MG  ≤ 3.5 mg/L (25 vs. 43 months;  p = 
 0.006;  Fig. 1 b). The level of β 2 -MG ( ≤ 3.5 vs. >3.5 mg/L) 
was a predictor in univariate but not in multivariate anal-
ysis ( p =  0.004, HR 1.698, 95% CI 1.2–2.4;  Table 3 ).  Cyto-
genetic risk stratification had no significant influence on 
OS, but high risk was significantly associated with infe-
rior PFS as compared to intermediate risk and standard 
risk (median 17 vs. 21 vs. 32 months;  p =  0.018;  Fig. 1 c). 
High risk versus standard risk was also an independent 
adverse factor for PFS ( p =  0.015; HR 2.398, 95% CI 1.2–
4.9;  Table 3 ) in univariate but not in multivariate analysis.
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 Fig. 1. Analyses of prognostic factors for progression-free survival 
(PFS) in relation to age  ≤ 60 vs. >60 years at autologous stem cell 
transplantation (ASCT) ( a ) and β 2 -microglobulin  ≤ 3.5 vs. 3.5 
mg/L at diagnosis ( b ), as well as depending on cytogenetic risk 
stratification at diagnosis ( c ). 
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 Survival according to the Number of Induction 
Regimes in Combination with Melphalan 
HDCT-ASCT 
 Patients received 1–5 induction regimens before 
ASCT, whereby 63% ( n = 176) of them received only 1 
induction regimen ( Table 2 ). Patients with 1 induction 
regimen showed significantly better median OS than pa-
tients with 2 or  ≥ 3 induction regimens (72 months, 95% 
CI 59.5–84.6; vs. 54 months, 95% CI 35.9–72.6; vs. 30 
months, 95% CI 9.5–74.8;  p =  0.003;  Fig. 2 a). To evaluate 
a possible effect of changing therapeutic and ASCT strat-
egies over time, we divided the entire cohort according to 
2 time periods, one from 1996 to 2004 and the other from 
2005 to 2012. Indeed, median OS was significantly better 
for myeloma patients treated in the later period (2005–
2012) with 71 versus 52 months in patients treated from 
1996 to 2004 ( p =  0.027;  Fig. 2 b). 
 Impact of Novel Myeloma Therapies in Combination 
with Melphalan HDCT-ASCT 
 As the entire cohort was treated over a time period of 
approximately 16 years (1996–2012), induction therapy 
consisted mainly of “traditional” regimens, e.g., the Al-
exanian protocol melphalan/prednisone (MP), idarubi-
cin/dexamethasone (ID), or vincristine/doxorubicin/
dexamethasone (VAD) in the first half of this period, and 
mainly of the “novel” therapies based on bortezomib, tha-
lidomide, and/or lenalidomide in addition to corticoste-
roids in the second half of the period ( Table 2 ). Based on 
our data and in accordance with respective approval dates 
of the novel compounds, the novel regimens were mainly 
applied after the year 2000 (data not shown). 
 In order to look for the impact of induction therapy 
with these novel compounds followed by melphalan 
HDCT-ASCT, we compared OS of NDMM patients 
who received either a traditional regimen or a novel 
regimen before ASCT. Follow-up data were available 
for  n = 245 patients. Median OS was significantly worse 
in NDMM patients ( n = 158) receiving induction ther-
apy with a traditional regimen than in NDMM patients 
( n = 87) treated with a novel compound (58 months, 
95% CI 47.2–68.7; vs. 69 months, 95% CI not available; 
 p =  0.01;  Fig. 3 ). There was no significant impact on PFS 
though. 
 Patient Characteristics at ASCT  
 Comparing the results of patients receiving single ver-
sus tandem ASCT, we refrained from statistical analyses 
of survival due to a selection bias of patients for the dif-
ferent transplant approaches (mainly patients with poor 
response to induction therapy were candidates for tan-
dem ASCT), and due to the limited number of patients 
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 Fig. 2. Overall survival (OS) according to the number of induction therapies ( a ) and the time of autologous stem 
cell transplantation (ASCT) ( b ).  a OS of myeloma patients who received 1, 2, or  ≥ 3 induction regimens.  b OS  of 
myeloma patients receiving ASCT within 2 time periods: 1996–2004 and 2005–2012. 
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who underwent tandem ASCT ( n = 34). Thus, we rather 
focused on the descriptive analysis of treatments and re-
sponse rates in both groups, which can be found as online 
supplementary Tables 1 and 2.
 Survival in Relation to Hematological Response 
 Hematological response rates of the entire cohort be-
fore and after ASCT are depicted in  Table 1 . In order to 
draw conclusions about survival in relation to hemato-
logical response, we divided the entire cohort into sub-
groups (SG). Patients with a very good PR (VGPR) or 
better were assigned to SG-1, whereas patients with a PR 
or worse were allocated to SG-2. Patients in SG-1 before 
ASCT ( n = 66) showed a significant advantage in OS com-
pared to the 204 patients in SG-2 before ASCT (median 
72 vs. 54 months;  p =  0.006; further details not shown), 
whereas no significant impact on PFS was observed. Ap-
proximately 41% of the patients ( n = 130) reached a 
VGPR or better  ≥ 100 days after ASCT. In accordance 
with previous literature  [37] , patients responding to 
ASCT with VGPR or better (SG-1 after ASCT,  n = 130) 
 ≥ 100 days after ASCT showed a significant benefit in 
 median OS compared to patients responding with PR or 
worse (SG-2 after ASCT,  n = 127) with 89 versus 53 
months ( p =  0.001). Again, there was no significant influ-
ence on PFS. SG-1 versus SG-2 before ASCT was a sig-
nificant prognostic factor for OS in univariate analysis 
though ( p = 0.007, HR 2.303, 95% CI 1.3–4.2;  Table 3 ). 
After ASCT, SG-1 versus SG-2 was a significant prognos-
tic factor for OS in both univariate ( p =  0.001, HR 1.967, 
95% CI 1.3–2.9, respectively) and multivariate analysis 
( p =  0.021, HR 2.860, 95% CI 1.2–7.0;  Table 3 ). Addition-
ally, we analyzed the distribution of both SGs within the 
2 time periods (1996–2004 and 2005–2012). The percent-
age of patients with at least VGPR or better was signifi-
cantly higher in the second period with 65% (99 of 152 
patients) as compared to 30% (31 of 105 patients) in the 
first period ( p < 0.001).
 Therapy after ASCT 
 The regimens used over time for treatment after 
ASCT, including consolidation, maintenance, and sal-
vage therapy, are shown in  Table 2 . For salvage therapy, 
74% of the patients (102 of 138) received treatment with 
novel compounds ( Table 2 ). Decisions for/against in-
tervention after ASCT were mainly based on benefit/
risk estimation according to the disease history of the 
individual patient and were influenced by available data 
over the time period of observation of this cohort. In 
some patients, they were determined by the study pro-
tocol. 
 Discussion 
 Here, we present a retrospective analysis of 320 my-
eloma patients treated with ASCT following melphalan 
HDCT in the period from 1996 to 2012. As we aimed to 
investigate an unselected patient cohort, patients were 
treated outside clinical trials and some within different 
study protocols. Thus, they should not be included in fu-
ture meta-analyses not based on single patient record 
forms to prevent multiple assessments of individuals. 
 The median PFS and OS observed in this analysis are 
comparable to those observed in large prospective trials 
on ASCT in myeloma patients  [2–4] , and our results cor-
roborate the efficacy of HDCT-ASCT with a low TRD 
rate of 3%.
 In accordance with the previous literature  [37, 38] , pa-
tients in our cohort responding to ASCT with a good re-
mission (SG-1 after ASCT) showed a significantly better 
80
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 Fig. 3. Overall survival (OS) depending on traditional versus nov-
el induction therapies. OS of newly diagnosed multiple myeloma 
patients who received only first-line induction either with a tradi-
tional or a novel regimen before autologous stem cell transplanta-
tion (ASCT). 
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OS as compared to SG-2 patients (median 89 vs. 53 months, 
 p =  0.001). Indeed, the Royal Marsden group suggested 
that patients with VGPR or better after the first ASCT 
should not approach tandem transplant but rather con-
tinue with maintenance chemotherapy and undergo sal-
vage transplantation in case of progression  [39] . This is 
currently being studied in a randomized design by the Ger-
man Study Group on Multiple Myeloma DSMM XIV trial. 
 For myeloma patients, age was demonstrated to be a 
crucial prognostic factor concerning survival  [24, 25] . In 
our analysis, patients >60 years at the time of ASCT had 
a worse PFS in comparison to younger patients (26 vs. 41 
months,  p < 0.001), whereas OS differences were not sig-
nificant. In general, >60% of patients with MM are >65 
years at diagnosis, with a median of 70 years  [40] . Even 
though ASCT and novel compounds such as bortezomib, 
lenalidomide, and thalidomide markedly improved sur-
vival of myeloma patients, this improvement was age spe-
cific  [24, 25] . In a report of the European Myeloma Net-
work, the 5-year relative survival of patients <50 years at 
diagnosis was 45% in the 1990s and rose to 57% in 2002. 
In contrast, survival increased by only 5% in patients >60 
years, and almost no improvement was seen in patients 
>70 years  [41] . Thus, application of ASCT to older pa-
tients should be considered cautiously and based on indi-
vidual patient data.
 We were able to show that myeloma patients with only 
1 induction regimen before ASCT had a better OS than 
patients with 2 or  ≥ 3 induction regimens (median 72 vs. 
54 months vs. 30 months;  p =  0.003). This may be ex-
plained by the fact that patients who were receiving >1 
induction regimen before HDCT-ASCT were poor re-
sponders to the first induction therapy and had per se a 
worse outcome than patients proceeding to melphalan 
HDCT-ASCT after only 1 induction regimen.
 In our single-center analysis, NDMM patients treated 
with traditional regimens including MP, CD, ID, and 
VAD as part of the first induction therapy before melpha-
lan HDCT-ASCT had an inferior OS as compared to pa-
tients treated with the novel compounds (median 58 vs. 
69 months,  p =  0.01). As these novel myeloma drugs, es-
pecially lenalidomide and bortezomib, were mainly ap-
plied in the new millennium for induction therapy as well 
as salvage therapy, this could explain why patients from 
our cohort treated in the period from 2005 to 2012 had a 
better OS than patients treated from 1996 to 2004. Im-
provements in microbiological analysis, antibiotic regi-
mens, and other developments in supportive care in re-
cent years may also have contributed to this survival ad-
vantage in the later period. 
 Randomized trials prospectively compared the out-
come of NDMM patients treated with the older drugs 
 versus the novel regimens as part of combined induction 
therapy followed by ASCT and have shown improved 
 response rates and prolonged PFS upon the use of the 
novel therapies, e.g. bortezomib/dexamethasone and 
bortezomib/thalidomide/dexamethasone. In the IFM 
2005-01 study, for example, bortezomib/dexamethasone 
induction was superior to vincristine/Adriamycin/dexa-
methasone before and after ASCT  [42] . Also, the ran-
domized phase 3 PETHEMA/GEM study showed that in-
duction with the triplet vincristine/Adriamycin/dexa-
methasone resulted in better response rates before and 
after ASCT and an improved PFS than thalidomide/dexa-
methasone or conventional chemotherapy with added 
bortezomib  [43] . Further randomized trials are necessary 
to evaluate the long-term effects of these novel com-
pounds with and without consecutive ASCT. Neverthe-
less, these studies were prospective, including an inten-
tion-to-treat analysis focusing on induction therapy, 
whereas this report is a retrospective as-treated analysis 
and only included patients who underwent ASCT and 
who, in part, also received salvage therapy with the novel 
compounds.
 In conclusion, melphalan HDCT-ASCT remains the 
gold standard for the treatment of myeloma patients. 
However, the most prominent outcome of this retrospec-
tive analysis of our complete monocenter patient cohort 
is that no survival plateaus could be observed, indicating 
that this approach does not have a curative potential. This 
is also in agreement with several other trials  [7–9] and 
underlines the urgent medical need for further research 
on drugs affecting additional targets. Novel compounds 
such as the immunomodulatory drug pomalidomide, the 
next-generation proteasome inhibitors carfilzomib and 
ixazomib, panobinostat, a pan-histone deacetylase inhib-
itor, and the monoclonal antibodies elotuzumab and da-
ratumumab already show promising results in the treat-
ment of myeloma patients  [44–49] .
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